| Literature DB >> 34210059 |
Manoj Kumar Mahata1, Ranjit De1,2, Kang Taek Lee1.
Abstract
Due to the unique properties of lanthanide-doped upconverting nanoparticles (Entities:
Keywords: bioimaging; biomedicine; biosensors; nanoparticles; oncotherapy; optogenetics; upconversion luminescence
Year: 2021 PMID: 34210059 PMCID: PMC8301434 DOI: 10.3390/biomedicines9070756
Source DB: PubMed Journal: Biomedicines ISSN: 2227-9059
Upconversion emission of various RE-doped materials.
| Host Material | Excitation Wavelength (nm) | Dopant Ions | Major Emission Bands | Reference | ||
|---|---|---|---|---|---|---|
| Blue | Green | Red | ||||
| CaMoO4 | 980 nm | Yb3+/Er3+ | 475 | 530, 552 | 656 | [ |
| NaYF4 | 980 nm | Yb3+/Tm3+ | 460, 477 | 650 | [ | |
| NaGdF4 | 980 nm | Ho3+/Yb3+ | 487 | 541 | 647, 751 | [ |
| Y2O3 | 980 nm | Yb3+/Er3+ | 487 | 522, 554 | 664 | [ |
| LaF3 | 980 nm | Yb3+/Tm3+ | 475 | 800 | [ | |
| LaF3 | 980 nm | Yb3+/Er3+ | 521, 545 | 660 | [ | |
| Na2Y2B2O7 | 980 nm | Yb3+/Er3+ | 476, 488 | 525, 550 | 660 | [ |
| YVO4 | 980 nm | Yb3+/Er3+ | 525, 554 | 661 | [ | |
| YVO4 | 980 nm | Yb3+/Ho3+ | 538, 548 | 655 | [ | |
| BaTiO3 | 980 and 800 nm | Yb3+/Er3+ | 476 | 563 | 650 | [ |
| BaTiO3 | 980 nm | Yb3+/Ho3+ | 538, 548 | 655 | [ | |
| Gd2Mo3O9 | 980 nm | Yb3+/Er3+ | 527, 547 | 660 | [ | |
Figure 1Schematic representation of basic upconversion processes [23]. (a) excited stte absorption; (b) energy transfer upconversion; (c) photon avalanche; (d) co-operative upconversion; (e) energy migration upconversion.
Some examples of UCNPs and their biomedicine applications along with excitation and emission wavelengths.
| UCNP | Excitation/Emission Wavelength (nm) | Application | Reference |
|---|---|---|---|
| NaLuF4:Yb3+,Tm3+@SiO2-GdDTPA | 980/800 | T1 MR, CT and NIR-I imaging | [ |
| LiYF4:Yb3+/Tm3+@SiO2@GPS@CH/PhL/PEGBA | 980/792 | Drug delivery and NIR-I imaging | [ |
| NaYbF4:2%Tm3+ | 980/800 | CT and NIR-I imaging | [ |
| NaYF4:Yb3+,Tm3+@FexOy | 980/800 | T2 MR, CT and NIR-I imaging | [ |
| CaF2:Tm3+,Yb3+ | 920/800 | NIR-I imaging | [ |
| NaYF4:Nd3+@NaLuF4@PDA18 | 808/1060 | NIR-II, CT imaging and PTT | [ |
| NaYF4:Yb,Nd@CaF2-PAA | 808/980, 1350 | Multiplexed NIR imaging | [ |
| NaErF4:2%Ho@NaYF4 | 1530/980, 1180 | Biosensing | [ |
| Nd3+: LaF3 | 808/900, 1060 | Sub-tissue thermal sensing | [ |
| NaYbF4:Tm3+ | 915/800 | NIR-I imaging | [ |
| NaDyF4:10%Nd-GA-Fe | 808/1050 | NIR-II, T2 MR imaging and PTT | [ |
| NaYF4:Yb,Ho/Pr/Tm/Er@NaYF4 | 980/1185/1310/1475/1525 | Disease-targeted NIR-II imaging | [ |
| NaGdF4:Yb,Er@NaGdF4:Nd,Yb-RB | 808/970 | T2 MR, NIR imaging and PDT | [ |
Figure 2(a) ANG/PEG-UCNPs: a dual mode targeting system for BBB crossing and targeting the glioblastoma. (b) Glioblastoma-bearing brain images after 1 h of intravenous injection with 5-ALA (excitation, 470 nm; emission, 650 nm) and ANG/PEG-UCNPs, PEG-UCNPs (excitation, 980 nm; emission, 800 nm); scale bar: 100 µm [85].
Figure 3Design of PDA@UCNP-PEG/Ce6. (A) Scheme for synergistic phototherapy. Upon laser irradiation, the UCNP-based system can ablate the tumor, tumor-associated antigens (TAA) are released and the antitumor immunity is triggered. Finally, it helps the inhibition of tumor metastasis. (B) The UCNP structure: core for PTT and the shell for PDT. (C) TEM images of PDA@UCNP. (D) Temperature variation with irradiation time of PDA@UCNP nanoparticles (2 mg mL−1). (E) Ce6 absorption and PDA@UCNP emission upon 980 nm laser excitation. (F) 1O2 generation comparison upon 1 Wcm−2 laser irradiation. Adapted with permission from [91].
Figure 4(A) Fe3+ -linked carrier: UCNP (core) and Dox (absorbed in the polymer shell). (B) Anticancer mechanism of the UCNP-based system. ① Passive accumulation of DGU:Fe/Dox with extended circulation and enhanced EPR. ② Change from DGU:Fe/Dox (negative) to GU:Fe/Dox (positive) at tumor site driven by pH activation. ③ Lysosome escape of GU:Fe/Dox through proton sponge. ④ Deconstruction of NIR-responsive system under the action of UCNP. 2464 Apoptosis of released Dox in the cell nucleus. ⑥ Ferroptosis of ROS with tumor cellular H2O2 at the cytoplasm. Adapted with permission from [100].
Figure 5(a) Schematic presentation of the UCNPs@Au-DOX synthesis, luminescence (UCL)/magnetic resonance (MR) imaging, photothermal therapy (PTT), and chemotherapy. (b) High-accuracy PTT using csUCNP@C. (b1) Schematic illustration of PTT. (b2) Images of HeLa cells with photothermal ablation (b3) PTT of HeLa cells upon 730 nm light excitation for 5 min. csUCNP@C-labeled cells exhibited a strong upconversion signal in the cytoplasm (green). (b4) Amplified image of (b3). (c) PDT/PTT effects on ALTS1C1 cells. (c1) Cytotoxicity of mTHPC, free IR-780, IMNPs, and ANG-IMNPs upon 808 nm or 980 nm laser light. (c2) Cytotoxicity of PTT and PDT; symbols and error bars are mean ± S.D. ** p < 0.01. (c3) Thermal images and (c4) temperature rise profiles upon irradiation. (c5) Laser scanning confocal microscopy images and the corresponding quantitative comparison of in vitro ROS generation in ALTS1C1 cells; singlet oxygen sensor green staining shown in green; blue shows cell nuclei stained with DAPI; scale bar: 20 μm. The 660 nm light generated due to upconversion reaction of the NIR laser inside the cancer cells, increasing fluorescence intensity. Adapted with permission from [85,111,114].
Figure 6(a) (a1–a5) Live mouse anatomy sections prior to injection of UC-α-CD. (a6–a10) Anatomy sections after 35 min post-intravenous injection of UC-α-CD. Figure (a1,a6) with a dashed line indicates the mouse position. (a7–a10) suggests UC-α-CD localization. (a11) Three-dimensional image collection. (a12) Analyzed area related section. (b) (b1) The setup for a wide-field epi-fluorescence microscopy. The 980 nm CW laser is the excitation source for UCNPs; the 532 nm diode laser is the light source for RFP; the acronyms used in the diagram are as follows:RC—reflective collimator; LC—live-cell chamber; S—sample; F—optical fiber; PS—piezo objective scanner; Obj—objective lens; L—lens; DM—dichroic mirror; T—tube lens; M—mirror. (b2) Scheme for scanning of the objective lens. (c) Early state colocalizations of UCNPs with early endosomes or late endosomes in tau aggregated SH-SY5Y cell. (c1) Control 20 min (955 frame), (c2) forskolin 20 min (739 frame), (c3) okadaic acid 20 min (771 frame), (c4) control 2 h (991 frame), (c5) forskolin 2 h (972 frame), and (c6) okadaic acid 2 h (974 frame). Magenta: UCNPs; green: early endosome; cyan: late endosome. Adapted with permission from [134,141,142].
Figure 7(a) Schematic description of the UCNP surface modification and FRET based on donor UCNPs and acceptor rhodamine. (b) UC emission spectra under 980 nm, (Inset: the variation of relative UC emission intensity at a 540 nm to 651 nm ratio upon different amount of Cys. (c) UV–Vis absorption titration spectra (Inset: the linear response of the absorption peak intensity at 562 nm and Cys concentration) of RHO functionalized UCNPs with a gradual increment of Cys. Reproduced with permission from [144].
Figure 8(a) Schematic illustration of ATP sensing using a resonance energy transfer between ssDNA-UCNPs. (b) Upconversion spectra of ssDNA-UCNPs in Tris-HCl buffer after (dashed line) and before (solid line) incubation with GO. (c) Upconversion emission of PAA-UCNPs in Tris-HCl buffer after (dashed line) and before (solid line) the addition of GO. (d) Upconversion spectra of UCNPs-GO in the presence of 0–2 mM ATP. (e) Plot of upconversion emission intensity (at 547 nm) vs. ATP concentration. Reproduced with permission from [145].
Figure 9(a) Upconversion spectrum of DNA-AgNPs/UCNP at various concentrations of H2O2. (b) 450 nm emission enhancement (F/F0) on increasing the amount of H2O2 in DNA-AgNPs/UCNP; F and F0 correspond to the upconversion emission intensity in the presence or absence of H2O2, respectively, in the system. Adapted with permission from [149].
Figure 10(a) Schematic description of the developed nanoprobe and its working principle. (b) Black line, upconversion emission upon 980 nm; blue line, absorption spectrum of FITC; red line, FITC emission upon 488 nm laser excitation. (c) Absorption spectra of FITC in various pH values. (d) Variation of 808 nm excited upconversion emission spectra of FITC-conjugated core–shell–shell nanoprobes with pH; inset shows the 474 nm band. (e) Variation of 474 nm, 643 nm and their ratio (474 to 643 nm) with pH values ranging from 3 to 8 [157].